



30.05.2022

To,  
Corporate Services Department,  
BSE Ltd.,  
Phiroze Jeejeebhoy Tower,  
Dalal Street,  
Mumbai- 400001

Dear Sir,

**Sub: Outcome Of Board Meeting For The Approval of Audited Financial Results For The Fourth Quarter And Year Ended 31<sup>st</sup> March, 2022 And Recommendation Of Dividend**

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the Board of Directors, at its meeting held today i.e. **Monday 30<sup>th</sup> May, 2022, at 903-909, 9<sup>th</sup> Floor, Bigjos Tower, Netaji Subhash Place, Delhi-110034**, have inter-alia approved the Standalone and Consolidated Audited Financial Results for the quarter and year ended 31<sup>st</sup> March, 2022.

In terms of the Provisions of Regulation 33 and 52(4) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are enclosing the following:

1. Audited Standalone financial results of the Company for the quarter and year ended 31<sup>st</sup> March, 2022 along with the Audit Report on the standalone financial statements.
2. Audited Consolidated financial results of the Company for the quarter and year ended 31<sup>st</sup> March, 2022 along with the Audit Report on the consolidated financial statements.
3. The disclosures under Regulation 52(4) of the Listing Regulations forms part of the standalone financial results of the Company for the year ended 31<sup>st</sup> March, 2022.
4. Declaration that the statutory auditors have Issued audit reports with unmodified opinion on financial statements.

**R.O. & Works:** Unit I: A-902 A, RIICO Industrial Area, Phase-III, Bhiwadi-301019, Rajasthan  
Unit II: E-540, Industrial Area, Chopanki, Bhiwadi-301019, Rajasthan

**E-mail:** [marketing@titanbiotechltd.com](mailto:marketing@titanbiotechltd.com)

**Website:** [www.titanbiotechltd.com](http://www.titanbiotechltd.com) | [www.titanmedia.in](http://www.titanmedia.in)



# TITAN BIOTECH LTD.

AN ISO 9001:2015 CERTIFIED COMPANY



Office : 903-909, 9<sup>th</sup> Floor, Bigjos Tower, Netaji Subhash Place, Delhi-110034, India  
Tel. : 011-27355742, 71239900 (44 Lines) | Fax : +91-11-47619811 | CIN: L74999RJ1992PLC013387

Further, the Board of Directors have recommended a dividend of Rs. 1.50/- (Rupees One Fifty Paise Only) per equity share for the Financial Year ended on 31<sup>st</sup> March, 2022. The said dividend, if declared at the ensuing Annual General Meeting, will be credited/dispatched to the eligible shareholders after the AGM within the limit as prescribed under the Companies Act, 2013 and other applicable laws.

The meeting of Board of Directors commenced at 03:00 P.M. and concluded at 05:25 P.M.

The above information will be available on the website of the S company i.e <https://titanbiotechltd.com> and BSE Ltd i.e [www.bseindia.com](http://www.bseindia.com) .

Request to kindly take this information on record and acknowledge.

Thanking you,  
Yours faithfully,  
For Titan Biotech Limited

  
Charanjit Singh  
Company Secretary  
Membership Number: A12726

Encl. as above

**R.O. & Works:** Unit I: A-902 A, RIICO Industrial Area, Phase-III, Bhiwadi-301019, Rajasthan  
Unit II: E-540, Industrial Area, Chopanki, Bhiwadi-301019, Rajasthan  
**E-mail:** [marketing@titanbiotechltd.com](mailto:marketing@titanbiotechltd.com)  
**Website:** [www.titanbiotechltd.com](http://www.titanbiotechltd.com) | [www.titanmedia.in](http://www.titanmedia.in)



# TITAN BIOTECH LTD.

AN ISO 9001:2015 CERTIFIED COMPANY



Office : 903-909, 9<sup>th</sup> Floor, Bigjos Tower, Netaji Subhash Place, Delhi-110034, India  
Tel. : 011-27355742, 71239900 (44 Lines) | Fax : +91-11-47619811 | CIN: L74999RJ1992PLC013387

To,  
Corporate Services Department,  
BSE Ltd.,  
Phiroze Jeejeebhoy Tower,  
Dalal Street,  
Mumbai- 400001

Date: 30.05.2022

Dear Ma'am/Sir,

**Scrip Code: 524717**

**Sub: Declaration Pursuant to Regulation 33(3) (d) of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015 for Unmodified Opinion**

I, Prem Shankar Gupta, Chief Financial Officer of Titan Biotech Limited hereby confirm and declare that the Statutory Auditors of the Company, M/s Sunita Agrawal & Co., Chartered Accountants (Firm Registration No. 515225C), have not expressed any modified opinion in their Audit Report pertaining to Annual Audited Financial Results (Standalone & Consolidated) of the Company for the financial year ended 31<sup>st</sup> March, 2022.

This declaration is given in compliance with Regulation 33(3) (d) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and SEBI Circular No. CIR/CFD/CMD/56/2016 dated May, 27, 2016 and SEBI vide Notification No. SEBI/LAD-NRO/GN/2016-17 /001 dated May 25, 2016.

Kindly take the above in your record.

**For and on behalf of  
Titan Biotech Limited**



**Prem Shankar Gupta  
Chief Financial Officer**

**R.O. & Works:** Unit I: A-902 A, RIICO Industrial Area, Phase-III, Bhiwadi-301019, Rajasthan  
Unit II: E-540, Industrial Area, Chopanki, Bhiwadi-301019, Rajasthan

**E-mail:** [marketing@titanbiotechltd.com](mailto:marketing@titanbiotechltd.com)

**Website:** [www.titanbiotechltd.com](http://www.titanbiotechltd.com) | [www.titanmedia.in](http://www.titanmedia.in)



**Independent Auditor's Report on the quarterly and year to date Audited Standalone Financial Results of the Company pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended**

To  
The Board of Directors of  
TITAN BIOTECH LIMITED

**Report on the audit of the Standalone Ind AS Financial Results**

**Opinion**

1. We have audited the accompanying Statement of Standalone Financial Results of TITAN BIOTECH LIMITED for the quarter ended 31/03/2022 and year ended 31/03/2022 ("the Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

In our opinion and to the best of our information and according to the explanations given to us, the standalone financial result:

- a. are presented in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended; and
  - b. gives a true and fair view in conformity with the recognition and measurement principles laid down in the applicable Indian Accounting Standards and other accounting principles generally accepted in India of the net profit and other comprehensive income and other financial information of company for the year ended 31/03/2022.
2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been compiled from the related Standalone financial statements which has been prepared in accordance with the Indian Accounting Standards prescribed under Section 133 of the Companies Act, 2013, read with the Companies (Indian Accounting Standards) Rules, 2015, as amended ("Ind AS"), and other accounting principles generally accepted in India. Our responsibility is to express an opinion on the Statement based on our audit of such Standalone financial result.

**Basis for Opinion**

3. We conducted our audit in accordance with the Standards on Auditing ("SAs") specified under Section 143(10) of the Companies Act 2013. Those Standards require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether the Statement is free from material misstatement.



Our responsibilities under those SAs are further described in the Auditor's Responsibilities for the audit of the standalone Annual Financial Results section of our report. We are independent of the company, in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India (the "ICAI") together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Act, and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the ICAI's Code of Ethics.

An audit involves performing procedures to obtain audit evidence about the amounts and the disclosures in the Statement. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the Statement, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the Company's preparation and fair presentation of the Statement in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the Company's internal financial control with reference to the Statement. An audit also includes evaluating the appropriateness of the accounting policies used and the reasonableness of the accounting estimates made by the Management, as well as evaluating the overall presentation of the Statement.

We believe that the audit evidence obtained by us is sufficient and appropriate to provide a basis for our audit opinion.

#### **Management's Responsibilities for the Standalone Ind AS Financial Results**

The Statement has been prepared on the basis of the Standalone annual financial statements. The board of directors of the company are responsible for the preparation and presentation of the Statement that gives a true and fair view of the net profit and other comprehensive income of the Company and other financial information in accordance with the applicable accounting standards prescribed under Section 133 of the Act read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the company and for preventing and detecting frauds and other irregularities, selection and application of appropriate accounting policies; making judgements and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the Statement that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the statement, the Board of Directors are responsible for assessing the Company's ability to continue as a going concern, disclosing as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the company or to cease operations, or has no realistic alternative but to do so.

The Board of Director are also responsible for overseeing the Company's financial reporting process.



## **Auditor's Responsibilities for the Audit of the Standalone Ind AS Financial Results**

Our objectives are to obtain other reasonable assurance about whether the Statement as a whole is free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of the Statement.

As part of an audit in accordance with SAs, we exercise professional judgement and maintain professional scepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the Statement, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under Section 143 (3) (i) of the Act, we are also responsible for expressing our opinion on whether the company has adequate internal financial controls with reference to financial statements in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.
- Conclude on the appropriateness of the board of Directors use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial results or if such disclosures are in, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the Statement, including the disclosures, and whether the Statement represents the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to



communicate with them all relationships and other matters that may reasonably be thought to bear on our independence and where applicable related safeguards.

4. Our opinion is not qualified in respect of any matter.

**Other Matter**

5. The Statement includes the results for the quarter and year ended 31/03/2022 being the balancing figure between audited figures in respect of the full financial year and the published unaudited year to date figures up to the third quarter of the current financial year which were subject to limited review by us as required under the Listing Regulations.



For Sunita Agrawal & co  
Chartered Accountants

FRN:  
515225C

FRN: 515225C

*Sunita*  
(CA Sunita Agrawal)

FCA Partner

M. No.095196

UDIN:- 22095196AJWXAJ9986

Place: Delhi  
Date: 30<sup>th</sup> May, 2022



# Sunita Agrawal & Co.

(Chartered Accountants)

**Independent Auditor's Report on the quarterly and year to date Audited Consolidated Financial Results of the Company pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended**

To  
The Board of Directors of  
TITAN BIOTECH LIMITED

**Report on the audit of the Consolidated Ind AS Financial Results**

## Opinion

1. We have audited the accompanying Statement of Consolidated Financial Results of TITAN BIOTECH LIMITED (Parent Company) and PEPTech BIOSCIENCES LIMITED associate (together referred to as "the Group") and its share of the net profit/(loss) after tax of its associates for the quarter ended 31/03/2022 and year ended 31/03/2022 ("the Statement"), being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

In our opinion and to the best of our information and according to the explanations given to us, and based on the consideration of the reports of the other auditors on separate financial statements and the other financial information of associates referred to in paragraph 5 below, the Statement:

- a. includes the results of the following entities: Peptech Biosciences Limited (Associate)
  - b. is presented in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended; and
  - c. gives a true and fair view in conformity with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standards and other accounting principles generally accepted in India of the consolidated total comprehensive income (comprising of net [profit/loss] and other comprehensive income/ loss) and other financial information of the Group for the year ended 31/03/2022.
2. This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been compiled from the related consolidated financial statements which has been prepared in accordance with the Indian Accounting Standards prescribed under Section 133 of the Companies Act, 2013, read with the Companies (Indian Accounting Standards) Rules, 2015, as amended ("Ind AS"), and other accounting principles generally accepted in India. Our responsibility is to express an opinion on the Statement based on our audit of such consolidated financial result.

## Basis for Opinion

3. We conducted our audit in accordance with the Standards on Auditing specified under Section 143(10) of the Companies Act 2013. Those Standards require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether the Statement is free from material misstatement.

Our responsibilities under those SAs are further described in the Auditor's Responsibilities for the audit of the standalone Annual Financial Results section of our report. We are



**Head Office :** 10, Giriraj Nagar, Inside Fort, Bharatpur (Rajasthan)-321001, Ph. : 05644-225679, M : 9899567901  
**Branch Office :** A-160, Boulevard, Hotel Crowne Plaza, Mayur Vihar, Phase-1, Delhi-110091, Ph. : 011-49868379

**E-mail :** sunitaca\_97@yahoo.com | sac.icai@gmail.com | info@taxfirst.in

**Web :** www.consultants.tax, www.taxfirst.in

independent of the company, in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India (the "ICAI") together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Act, and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the ICAI's Code of Ethics.

An audit involves performing procedures to obtain audit evidence about the amounts and the disclosures in the Statement. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the Statement, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the Parent's preparation and fair presentation of the Statement in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the Parent's internal financial control with reference to the Statement. An audit also includes evaluating the appropriateness of the accounting policies used and the reasonableness of the accounting estimates made by the Management, as well as evaluating the overall presentation of the Statement.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure requirements) Regulations, 2015, as amended, to the extent applicable.

We believe that the audit evidence obtained by us and other auditors in terms of their reports referred to in paragraph 5 below, is sufficient and appropriate to provide a basis for our audit opinion.

#### **Management's Responsibilities for the Consolidated Ind AS Financial Results**

The Statement has been prepared on the basis of the Consolidated annual financial statements. The board of directors of the company are responsible for the preparation and presentation of the Statement that gives a true and fair view of the net profit and other comprehensive income of the Company and other financial information in accordance with the applicable accounting standards prescribed under Section 133 of the Act read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the company and for preventing and detecting frauds and other irregularities, selection and application of appropriate accounting policies; making judgements and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the Statement that give a true and fair view and are free from material misstatement, whether due to fraud or error, which have been used for the purpose of preparation of the consolidated financial results by the Directors of parent company, as aforesaid.

In preparing the statement, the Board of Directors are responsible for assessing the Company's ability to continue as a going concern, disclosing as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the company or to cease operations, or has no realistic alternative but to do so.

The respective Board of Directors of the companies included in the group are also responsible for overseeing respective Company's financial reporting process.



## **Auditor's Responsibilities for the Audit of the Consolidated Ind AS Financial Results**

Our objectives are to obtain other reasonable assurance about whether the Statement as a whole is free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of the Statement.

As part of an audit in accordance with SAs, we exercise professional judgement and maintain professional scepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the Statement, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under Section 143 (3) (i) of the Act, we are also responsible for expressing our opinion on whether the company has adequate internal financial controls with reference to financial statements in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.
- Conclude on the appropriateness of the board of Directors use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial results or if such disclosures are in, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However future events or conditions may cause the Group any associates to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the Statement, including the disclosures, and whether the Statement represents the underlying transactions and events in a manner that achieves fair presentation.
- Obtain sufficient appropriate audit evidence regarding the financial results/financial information of the entities within the group and its associates to express an opinion on the consolidated financial results. We are responsible for the direction, supervision and performance of the audit of financial information of such entities included in the consolidated financial results of which we are the independent auditors. For the other entities included in the consolidated annual financial results, which have been audited by other auditors, such other auditors remain responsible for the direction, supervision and performance of audits carried out by them. We remain solely responsible for our audit opinion. Our responsibilities in this regard are further described in para (a) of the section titled "other Matters" in this audit report.

We communicate with those charged with governance of the parent company and such other entities included in the consolidated financial results of which we are the independent auditors regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.



We also provide those charged with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence and where applicable related safeguards.

We also performed procedure in accordance with circular no. CIR/CFD/CMD1/44/2019 issued by the Securities and Exchange Board of India under Regulation 33(8) of the listing regulations to the extent applicable.

4. Our opinion is not qualified in respect of any matter.

**Other Matter**

5. We did not audit the financial statements / financial information of Peptech Biosciences Limited which was subsidiary of the parent upto 15/02/2022 and due to issue of new shares by Peptech Biosciences Limited and reduction in holding of parent company its status was change to associate included in the consolidated financial results, whose financial statements / financial information which include share of Profit of associate of Rs. 1902969.88 for the year ended 31st March, 2022, as considered in the consolidated financial results, whose financial statements / financial information have not been audited by us. These financial statements / financial information have been audited by other auditors whose reports have been furnished to us by the Management and our opinion on the consolidated financial results, in so far as it relates to the amounts and disclosures included in respect of the associates is based solely on the reports of the other auditors and the procedures performed by us as stated in paragraph 3 above.

Our opinion on the Statement is not modified in respect of the above matters.

6. The Statement includes the results for the quarter and year ended 31/03/2022 being the balancing figure between audited figures in respect of the full financial year and the published unaudited year to date figures up to the third quarter of the current financial year which were subject to limited review by us as required under the Listing Regulations.

 For Sunita Agrawal & co  
Chartered Accountants  
FRN: 515225C  
*Sunita*  
(CA Sunita Agrawal)  
FCA Partner  
M. No.095196

UDIN:- 22095196AJWXKX6729

Place: Delhi  
Date: 30th May, 2022

**TITAN BIOTECH LIMITED**  
**Regd. Office :- A-902 A, RIICO Industrial Area, Phase III, Bhiwadi, Rajasthan-301019**  
**Phone No. 011- 71239900, Email : hrd@titanbiotechltd.com www.titanbiotechltd.com CIN : L74999RJ1992PLC013387**  
**STATEMENT OF STANDALONE AUDITED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED 31ST MARCH, 2022**  
**(Rs. IN LAKHS) except for EPS**


Sr. No	PARTICULARS	STANDALONE				
		QUARTER ENDED			YEAR ENDED	
		31.03.2022 AUDITED	31.12.2021 UNAUDITED	31.03.2021 AUDITED	31.03.2022 AUDITED	31.03.2021 AUDITED
1	<b>INCOME</b>					
	Revenue from operations	3,108.67	2,896.88	2,941.33	12,354.89	12,245.94
	Other Income	38.13	18.82	20.03	94.13	65.99
	<b>Total Income</b>	<b>3,146.80</b>	<b>2,915.70</b>	<b>2,961.36</b>	<b>12,449.02</b>	<b>12,311.93</b>
2	<b>EXPENSES</b>					
	Cost of Materials Consumed	1,446.56	1,498.98	1,584.60	5,912.24	5,554.05
	Changes in inventories of Finished Goods, Stock-in-Trade and Work-in-Progress	(36.41)	(48.86)	(69.27)	(17.30)	(222.63)
	Employee Benefit Expenses	421.30	349.80	367.12	1,433.00	1,204.36
	Finance Costs	17.81	17.51	39.56	78.39	127.54
	Depreciation and Amortization Expenses	69.20	57.23	77.27	236.91	210.41
	Other Expenses	586.77	449.46	438.56	1,908.88	1,529.61
	<b>Total Expenses</b>	<b>2,505.23</b>	<b>2,324.12</b>	<b>2,437.84</b>	<b>9,552.12</b>	<b>8,403.34</b>
3	Profit/(loss) before exceptional items and tax (1-2)	641.57	591.58	523.52	2,896.90	3,908.59
4	Exceptional Items			(41.45)	-	(32.44)
5	Profit/ (loss) before tax (3+4)	641.57	591.58	482.07	2,896.90	3,876.15
6	Tax expense:					
	I) Current Tax	175.35	145.27	148.18	735.07	984.75
	II) Deferred Tax	(14.06)	3.57	(4.23)	(6.57)	13.11
	(III) Earlier year taxes	(0.01)	(0.02)	-	(0.03)	1.02
	<b>Total Tax (I+II)</b>	<b>161.28</b>	<b>148.82</b>	<b>143.95</b>	<b>728.47</b>	<b>998.88</b>
7	Profit (Loss) for the period after Tax (5-6)	<b>480.29</b>	<b>442.76</b>	<b>338.12</b>	<b>2,168.43</b>	<b>2,877.27</b>
8	<b>Other comprehensive income (Net of Tax)</b>					
A.	Items that will not be reclassified to profit or loss					
	Re-measurement gain on defined benefit plans	(2.08)		6.04	(2.08)	6.04
B	(i) Items that will be reclassified to profit or loss	-		-		
	(ii) Income tax relating to items that will be reclassified to profit or loss	-		-		
	<b>Total Other Comprehensive Income for the period (A+B)(net of taxes)</b>	<b>(2.08)</b>		<b>6.04</b>	<b>(2.08)</b>	<b>6.04</b>
9	<b>Total Comprehensive Income for the period (7+8)</b>	<b>478.21</b>	<b>442.76</b>	<b>344.16</b>	<b>2,166.35</b>	<b>2,883.31</b>
10	Paid-up equity share capital (Face Value of Rs. 10/- each)	826.37	826.37	826.37	826.37	826.37
11	Other Equity				7,798.04	5,755.64
12	Earnings per equity share (face value of Rs.10/- each) not annualised					
	(1) Basic	5.81	5.36	4.09	26.24	34.82
	(2) Diluted	5.81	5.36	4.09	26.24	34.82

**Notes:**

- The above audited standalone financial results for the quarter and year ended on 31.03.2022 have been reviewed by the Audit Committee and taken on record by the Board of Directors of the Company at its meeting held on May 30, 2022. The Statutory Auditors of the Company have carried out a limited review in terms of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements), 2015.
- Previous period figures are regrouped/reclassified in line with the current period.
- The Company has only one reportable business segment.
- The Company has elected to exercise the option permitted under section 115BAA of the Income Tax Act, 1961 as introduced by Taxation Law (Amendment) Ordinance 2019. Accordingly, the Company has recognized provision for income tax for the quarter and year ended on 31st March 2022 and remeasured its deferred tax balance on the basis of the rate prescribed in the said section.
- The total sale for the quarter ended 31.03.2022 includes sale of Products of Rs. 157.98 Lakhs and year ended of Rs.1082.51 Lakhs the demand for which arose due to Covid 19 Pandemic.**
- The standalone audited financial results have been prepared in accordance with the Indian Accounting Standards ("Ind AS") specified in the Companies (Indian Accounting Standards) Rules 2015 (as amended) under section 133 of the Companies Act 2013 (the "accounting principles generally accepted in India").
- During the year, the company paid Rs. 34.24 Lakhs towards Corporate Social Responsibility (CSR) expenditure.
- Figures for the quarter ended 31.03.2022 are the balancing figures between audited figures for the full year and the reviewed year to date figures up to the third quarter of respective financial year.
- Freight amount has been added in revenue from operation for the purpose of calculation of sales including GST in current year. Freight also added in total in other expenses to neutralise the impact of its addition in revenue in current year.
- The Board of Directors of the company has recommended a dividend of Rs. 1.50 per equity share for the financial year ended on 31st March, 2022. The Dividend will be paid after approval of the same by shareholders in the Annual General meeting.

For and on behalf of Board of Directors  
for TITAN BIOTECH LIMITED

*Suresh Chand Singla*  
SURESH CHAND SINGLA  
Managing Director  
DIN-00027706



Place : Delhi  
Dated : 30.05.2022

**TITAN BIOTECH LIMITED**

Regd. Office :- A-902 A RIICO Industrial Area, Phase III, Bhiwadi, Rajasthan-301019

Phone No. 011- 71239900, Fax No. +91-11-47619811 Email : hrd@titanbiotechltd.com www.titanbiotechltd.com CIN : L74999RJ1992PLC013387

**STATEMENT OF STANDALONE AUDITED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED 31ST MARCH, 2022**

(Rs. IN LAKHS) except for EPS


Sr. No.	PARTICULARS	STANDALONE				
		QUARTER ENDED		YEAR ENDED		
		31.03.2022 AUDITED	31.12.2021 UNAUDITED	31.03.2021 AUDITED	31.03.2022 AUDITED	31.03.2021 AUDITED
1	Total Income from Operations (Net)	3,146.80	2,915.70	2,961.36	12,449.02	12,311.93
2	Net Profit/(Loss) for the period (before tax,exceptional and/or extraordinary items)	641.57	591.58	523.52	2,896.90	3,908.59
3	Net Profit/(Loss) for the period before tax (after exceptional and/or extraordinary items)	641.57	591.58	482.07	2,896.90	3,876.15
4	Net Profit/(Loss) for the period after tax (after exceptional and/or extraordinary items)	480.29	442.76	338.12	2,168.43	2,877.27
5	Total comprehensive income for the period (comprising Profit/(Loss)for the period(after tax) and Other Comprehensive income(after tax)(refer note 3)	478.21	442.76	344.16	2,166.35	2,883.31
6	Paid-up Equity Share Capital ( Face value of Rs. 10/- per share)	826.37	826.37	826.37	826.37	826.37
7	Other Equity excluding Revaluation Reserves as per the balance sheet	-	-	-	7,798.04	5,755.64
8	Earning Per Share (of INR 10/- each)					
	(a) Basic	5.81	5.36	4.09	26.24	34.82
	(b) Diluted	5.81	5.36	4.09	26.24	34.82

**NOTES :**

- The above is an extract of the detailed format of standalone audited Financial Results for the quarter and year ended on 31.03.2022 filed with the BSE Limited Under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements ) Regulations, 2015. The full format of the Standalone audited Financial Results for the said quarter and year ended on 31st March 2022 are available on the website of BSE Limited at www.bseindia.com and on company website at www.titanbiotechltd.com.The statutory auditors have expressed an unmodified audit opinion on these results.
- The above audited standalone financial results for the quarter and year ended on 31.03.2022 have been reviewed by the Audit Committee and taken on record by the Board of Directors of the Company at its meeting held on May 30, 2022.The Statutory Auditors of the Company have carried out a limited review in terms of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirments), 2015.
- The Company has elected to exercise the option permitted under section 115BAA of the Income Tax Act, 1961 as introduced by Taxation Law(Amendment) Ordinance 2019.Accordingly, the Company has recognized provision for income tax for the quarter and year ended on 31st March 2022. and remeasured its deferred tax balance on the basis of the rate prescribed in the said section.
- The total sale for the quarter ended 31.03.2022 includes sale of Products of Rs. 157.98 Lakhs and year ended of Rs.1082.51 Lakhs the demand for which arose due to Covid 19 Pandemic.**
- The standalone audited financial results have been prepared in accordance with the Indian Accounting Standards ( 'Ind AS' ) specified in the Companies (Indian Accounting Standards) Rules 2015 (as amended) under section 133 of the Companies Act 2013 (the "accounting principles generally accepted in India").
- Figures for the quarter ended 31.03.2022 are the balancing figures between audited figures for the full year and the reviewed year to date figures up to the third quarter of respective financial year.
- Freight amount has been added in revenue from operation for the purpose of calculation of sales including GST in current year. Freight also added in total in other expenses to neutralise the impact of its addition in revenue in current year.
- During the year, the company paid Rs. 34.24 Lakhs towards Corporate Social Responsibility (CSR) expenditure.
- The Board of Directors of the company has recommended a dividend of Rs. 1.50 per equity share for the financial year ended on 31st March, 2022. The Dividend will be paid after approval of the same by shareholders in the Annual General meeting.

For and on behalf of Board of Directors  
for TITAN BIOTECH LIMITED

SURESH CHAND SINGLA  
Managing Director  
DIN-00027706



Place : Delhi


Dated : 30.05.2022

**TITAN BIOTECH LIMITED**  
**Standalone Balance Sheet as at 31st March, 2022**

(Rs. in Lakhs.)

Particulars	As at	
	31/03/2022 Audited	31/03/2021 Audited
<b>I ASSETS</b>		
<b>1. Non-Current Assets</b>		
a. Property, Plant and Equipment	2,554.21	2,497.62
b. Capital Work-in-Progress	363.39	27.05
c. Right of use Assets	933.84	196.94
d. Intangible assets	10.46	9.17
e. Financial Assets		
(i) Investments	403.12	127.50
(ii) Other Financial Assets	168.54	795.44
<b>Total Non-current assets</b>	<b>4,433.56</b>	<b>3,653.72</b>
<b>2. Current Assets</b>		
a. Inventories	3,467.97	2,682.82
b. Financial Assets		
(i) Trade receivables	1,635.91	1,611.72
(ii) Cash and cash equivalents	681.39	530.86
c. Current Tax Assets (Net)	-	-
d. Other Current Assets	537.36	137.89
<b>Total Current assets</b>	<b>6,322.63</b>	<b>4,963.29</b>
<b>TOTAL ASSETS</b>	<b>10,756.19</b>	<b>8,617.01</b>
<b>II. EQUITY AND LIABILITIES</b>		
<b>A Equity</b>		
a. Equity Share Capital	826.37	826.37
b. Other Equity	7,798.04	5,755.64
<b>TOTAL EQUITY</b>	<b>8,624.41</b>	<b>6,582.01</b>
<b>B Liabilities</b>		
<b>1. Non-Current Liabilities</b>		
a. Financial Liabilities		
(i) Borrowings	108.11	182.69
(ii) Lease liabilities	110.86	139.83
b. Deferred tax liabilities (Net)	127.55	134.82
c. Provisions	143.27	124.13
<b>Total Non-Current Liabilities</b>	<b>489.79</b>	<b>581.47</b>
<b>2. Current Liabilities</b>		
a. Financial Liabilities		
(i) Borrowings	471.77	570.90
(ii) Lease liabilities	28.97	25.02
(iii) Trade payables	415.99	268.47
(iv) Other financial liabilities	490.53	404.82
b. Other current liabilities	174.83	159.23
c. Provisions	28.51	17.00
d. Current Tax Liabilities (Net)	31.39	8.09
<b>Total Current Liabilities</b>	<b>1,641.99</b>	<b>1,453.53</b>
<b>TOTAL EQUITY AND LIABILITIES</b>	<b>10,756.19</b>	<b>8,617.01</b>

For and on behalf of Board of Directors  
for TITAN BIOTECH LIMITED

  
**SURESH CHAND SINGLA**  
Managing Director  
DIN-00027706



Place : Delhi

Date : 30.05.2022

**TITAN BIOTECH LIMITED**  
**Standalone Cash Flow Statement for the period ended 31st March, 2022**

(Rs. in Lakhs.)

Particulars	Year ended	Year ended
	31/03/2022	31/03/2021
	Audited	Audited
<b>A. CASH FLOW FROM OPERATING ACTIVITIES</b>		
Profit before Tax	2,896.90	3,876.15
<b>Adjustment for :</b>	-	-
Finance Costs	78.39	127.54
Provisions	27.87	25.30
Earlier year Taxes	0.03	(1.02)
Depreciation and Amortization Expenses	236.91	210.41
Operating profit before working capital changes	3,240.10	4,238.38
Changes in working Capital:		
Inventories	(785.15)	(268.79)
Trade and other Receivables	203.24	(1,260.71)
Trade and other Payables	248.83	65.34
Cash generation from Operation	2,907.02	2,774.22
Payment of Direct Taxes	(711.77)	(1,015.62)
<b>Net Cash generated/ (used) - Operating Activities</b>	<b>2,195.25</b>	<b>1,758.60</b>
<b>B. CASH FLOW FROM INVESTMENT ACTIVITIES</b>		
Purchase of Investment in shares	(275.63)	
Purchase of Fixed Assets (incl.Capital WIP)	(631.12)	(271.26)
Right of use assets	(736.90)	(146.03)
<b>Net Cash Generated/ (Used) - Investing Activities</b>	<b>(1,643.65)</b>	<b>(417.29)</b>
<b>C.CASH FLOW FROM FINANCING ACTIVITIES</b>		
Repayment of Long-term Borrowings	(74.58)	(665.13)
Repayment of Lease Liabilities	(25.02)	164.83
Proceeds/(Repayment) of Short-term Borrowings (Net)	(99.12)	(270.07)
Finance Cost paid	(78.39)	(127.54)
Dividend paid	(123.96)	(82.64)
<b>Net Cash Generated/ (Used) - Financing Activities</b>	<b>(401.07)</b>	<b>(980.55)</b>
<b>Net Increase/ (Decrease) in Cash and Cash Equivalents</b>	<b>150.53</b>	<b>360.76</b>
Add : Opening Cash and Cash Equivalents	530.86	170.10
<b>Closing Cash and Cash Equivalents (refer note-8)</b>	<b>681.39</b>	<b>530.86</b>

**Notes:**

- The Cash Flow Statements have been prepared under the indirect method as set out in Accounting Standard (AS) on Statement of Cash Flow (Ind AS-7).
- Figures in bracket represent outflows.
- Previous year's figures have been regrouped wherever considered necessary to conform to this year's classification.

Place : Delhi  
Date : 30.05.2022

For and on behalf of Board of Directors  
for TITAN BIOTECH LIMITED

*Suresh Chand Singla*  
**SURESH CHAND SINGLA**  
Managing Director  
DIN-00027706



TITAN BIOTECH LIMITED

Regd. Office :- A-902 A, RIICO Industrial Area, Phase III, Bhiwadi, Rajasthan-301019

Phone No. 011-71239900, Email : hrd@titanbiotechltd.com www.titanbiotechltd.com CIN : L74999RJ1992PLC013387

STATEMENT OF CONSOLIDATED AUDITED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED 31ST MARCH, 2022

(Rs. IN LAKHS) except for EPS

Sr. No	PARTICULARS	CONSOLIDATED				
		QUARTER ENDED			YEAR ENDED	
		31.03.2022	31.12.2021	31.03.2021	31.03.2022	31.03.2021
	AUDITED	UNAUDITED	AUDITED	AUDITED	AUDITED	
1	<b>INCOME</b>					
	Revenue from operations	3,293.59	3,642.69	3,556.52	15,280.97	14,223.72
	Other Income	39.41	22.83	25.30	102.25	78.84
	<b>Total Income</b>	<b>3,333.00</b>	<b>3,665.52</b>	<b>3,581.82</b>	<b>15,383.22</b>	<b>14,302.56</b>
2	<b>EXPENSES</b>					
	Cost of Materials Consumed	1,540.45	1,908.19	2,008.80	7,547.79	6,730.24
	Changes in Inventories of Finished Goods, Stock-in-Trade and Work-in-Progress	(37.32)	(44.65)	(119.25)	(60.16)	(273.41)
	Employee Benefit Expenses	442.90	406.57	423.89	1,613.74	1,405.23
	Finance Costs	20.34	34.02	49.36	128.26	166.76
	Depreciation and Amortization Expenses	70.55	62.44	83.92	253.84	221.73
	Other Expenses	605.43	503.41	515.40	2,079.92	1,749.01
	<b>Total Expenses</b>	<b>2,642.35</b>	<b>2,869.98</b>	<b>2,962.12</b>	<b>11,563.39</b>	<b>9,999.56</b>
3	Profit/(loss) before exceptional items and tax (1-2)	690.65	795.54	619.70	3,819.83	4,303.00
4	Exceptional Items	-	-	(41.44)	-	(32.44)
5	Profit/ (loss) before tax (3+4)	690.65	795.54	578.26	3,819.83	4,270.56
6	Tax expense:					
	I) Current Tax	189.66	196.87	174.91	970.33	1,085.57
	II) Earlier year taxes	-	1.45	(0.99)	1.69	0.56
	III) Deferred Tax	(13.97)	3.32	(4.41)	(7.50)	13.90
	Total Tax (I+II)	175.69	201.64	169.51	964.52	1,100.03
7	Profit (Loss) for the period after Tax (5-6)	<b>514.96</b>	<b>593.90</b>	<b>408.75</b>	<b>2,855.31</b>	<b>3,170.53</b>
8	<b>Share in Profit of Associate</b>	-	-	-	<b>19.03</b>	-
9	<b>Profit (Loss) for the period (7+8)</b>	<b>514.96</b>	<b>593.90</b>	<b>408.75</b>	<b>2,874.34</b>	<b>3,170.53</b>
10	<b>Other comprehensive income (Net of Tax)</b>					
A.	Items that will not be reclassified to profit or loss					
	Re-measurement gain on defined benefit plans	(2.08)	-	5.21	(2.08)	5.21
B	(i) Items that will be reclassified to profit or loss	-	-	-	-	-
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-
	Total Other Comprehensive Income for the period (A+B)(net of taxes)	(2.08)	-	5.21	(2.08)	5.21
11	<b>Total Comprehensive Income for the period (7+8)</b>	<b>512.88</b>	<b>593.90</b>	<b>413.96</b>	<b>2,872.26</b>	<b>3,175.74</b>
12	<b>Net profit attributable to:</b>					
	Owners of the holding company	498.70	523.05	376.11	2,533.30	3,033.52
	Non-controlling interest	16.25	70.86	32.64	322.01	137.01
13	<b>Other comprehensive income attributable to :</b>					
	Owners of the holding company	(1.71)	-	5.60	(1.71)	5.60
	Non-controlling interest	(0.37)	-	(0.39)	(0.37)	(0.39)
14	<b>Total Comprehensive Income attributable to (10+11)</b>					
	Owners of the holding company	496.99	523.05	381.71	2,531.59	3,039.12
	Non-controlling interest	15.88	70.86	32.25	321.64	136.62
15	Paid-up equity share capital (Face Value of Rs. 10/- each)	826.37	826.37	826.37	826.37	826.37
16	Other Equity				9,040.49	6,049.45
17	Earnings per equity share (face value of Rs.10/- each) not annualised					
	(1) Basic	6.03	6.33	4.55	30.66	36.71
	(2) Diluted	6.03	6.33	4.55	30.66	36.71

Notes:

- The above consolidated audited financial results for the quarter and year ended on 31.03.2022 have been reviewed by the Audit Committee and taken on record by the Board of Directors of the Company at their respective meeting held on May 30, 2022. The statutory auditors have expressed an unmodified audit opinion on these results. The results for the quarter and year ended March 31, 2022, are available on the BSE Limited website(bseindia.com) and on the company's Website(titanbiotechltd.com)
- The consolidated audited financial results for the quarter and year ended on 31.03.2022 include the results of following:-  
Associate Company - Peptech Biosciences Limited
- The Company has elected to exercise the option permitted under section 115BAA of the Income Tax Act, 1961 as introduced by Taxation Law(Amendment) Ordinance 2019. Accordingly, the Company has recognized provision for income tax for the quarter and year ended on 31 March 2022 and remeasured its deferred tax balance on the basis of the rate prescribed in the said section.
- The total sale for the quarter ended 31.03.2022 includes sale of Products of Rs. 157.98 Lakhs and year ended of Rs.1082.51 Lakhs the demand for which arose due to Covid 19 Pandemic.**
- Previous period figures are regrouped/reclassified in line with the current period.
- The Company has only one reportable business segment.
- The consolidated audited financial results have been prepared in accordance with the Indian Accounting Standards ("Ind AS") specified in the Companies (Indian Accounting Standards) Rules 2015 (as amended) under section 133 of the Companies Act 2013 (the "accounting principles generally accepted in India").
- Figures for the quarter ended 31.03.2022 are the balancing figures between audited figures for the full year and the reviewed year to date figures up to the third quarter of respective financial year.
- Freight amount has been added in revenue from operation for the purpose of calculation of sales including GST in current year. Freight also added in total in other expenses to neutralise the impact of its addition in revenue in current year.
- During the year, the company paid Rs. 34.24 Lakhs towards Corporate Social Responsibility (CSR) expenditure.
- Peptech Biosciences Limited had issued and allotted 9600000 partly paid equity shares on rights basis. after allotment the share holding of Titan Biotech Limited changed from 53.11% to 36.87%. The status of Peptech Biosciences Limited changed from subsidiary to associate due to change in percentag of shareholding on 16th Feb.,2022.
- The Board of Directors of the company has recommended a dividend of Rs. 1.50 per equity share for the financial year ended on 31st March, 2022. The Dividend will be paid after approval of the same by shareholders in the Annual General meeting.

For and on behalf of Board of Directors  
for TITAN BIOTECH LIMITED

  
SURESH CHAND SINGLA  
Managing Director  
DIN-0027706



Place : Delhi  
Dated :30.05.2022

TITAN BIOTECH LIMITED

Regd. Office :- A-902 A RIICO Industrial Area, Phase III, Bhiwadi, Rajasthan-301019

Phone No. 011-71239900, Email : hrd@titanbiotechltd.com www.titanbiotechltd.com CIN : L74999RJ1992PLC013387

STATEMENT OF CONSOLIDATED AUDITED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED 31ST MARCH, 2022

(Rs. IN LAKHS) except for EPS


S.NO.	PARTICULARS	CONSOLIDATED				
		QUARTER ENDED			YEAR ENDED	
		31.03.2022	31.12.2021	31.03.2021	31.03.2022	31.03.2021
		AUDITED	UNAUDITED	AUDITED	AUDITED	AUDITED
1	Total Income from Operations (Net)	3,333.00	3,665.52	3,581.82	15,383.22	14,302.56
2	Net Profit/(Loss) for the period (before tax, exceptional and/or extraordinary items)	690.65	795.54	619.70	3,819.83	4,303.00
3	Net Profit/(Loss) for the period before tax (after exceptional and/or extraordinary items)	690.65	795.54	578.26	3,819.83	4,270.56
4	Net Profit/(Loss) for the period after tax (after exceptional and/or extraordinary items)	514.96	593.90	408.75	2,874.34	3,170.53
5	Total comprehensive income for the period (comprising Profit/(Loss) for the period (after tax) and Other Comprehensive income (after tax) (refer note 3)	512.88	593.90	413.96	2,872.26	3,175.74
6	Paid-up Equity Share Capital (Face value of Rs. 10/- per share)	826.37	826.37	826.37	826.37	826.37
7	Other Equity excluding Revaluation Reserves as per the balance sheet					6,049.45
8	Earning Per Share (of INR 10/- each)					
	(a) Basic	6.03	6.33	4.55	30.66	36.71
	(b) Diluted	6.03	6.33	4.55	30.66	36.71

NOTES :

- The above is an extract of the detailed format of consolidated audited Financial Results for the quarter and year ended on 31.03.2022 filed with the BSE Limited Under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the consolidated audited Financial Results for the said quarter and year ended on 31st March 2022 are available on the website of BSE Limited at www.bseindia.com and on company website at www.titanbiotechltd.com.
- The above consolidated audited financial results for the quarter and year ended on 31.03.2022 have been reviewed by the Audit Committee and taken on record by the Board of Directors of the Company at their respective meeting held on May 30, 2022. The Statutory Auditors of the Company have carried out a Limited Review of the aforesaid results.
- The Company has elected to exercise the option permitted under section 115BAA of the Income Tax Act, 1961 as introduced by Taxation Law (Amendment) Ordinance 2019. Accordingly, the Company has recognized provision for income tax for the quarter and year ended on 31.03.2022 and remeasured its deferred tax balance on the basis of the rate prescribed in the said section.
- The total sale for the quarter ended 31.03.2022 includes sale of Products of Rs. 157.98 Lakhs and year ended of Rs.1082.51 Lakhs the demand for which arose due to**
- The consolidated audited financial results have been prepared in accordance with the Indian Accounting Standards ("Ind AS") specified in the Companies (Indian Accounting Standards) Rules 2015 (as amended) under section 133 of the Companies Act 2013 (the "accounting principles generally accepted in India").
- Figures for the quarter ended 31.03.2022 are the balancing figures between audited figures for the full year and the reviewed year to date figures up to the third quarter of respective financial year.
- Freight amount has been added in revenue from operation for the purpose of calculation of sales including GST in current year. Freight also added in total in other expenses to neutralise the impact of its addition in revenue in current year.
- During the year, the company paid Rs. 34.24 Lakhs towards Corporate Social Responsibility (CSR) expenditure.
- Pepetech Biosciences Limited had issued and allotted 9600000 partly paid equity shares on rights basis. after allotment the share holding of Titan Biotech Limited changed from 53.11% to 36.87%. The status of Pepetech Biosciences Limited changed from subsidiary to associate due to change in percentag of shareholding on 16th Feb.,2022.
- The Board of Directors of the company has recommended a dividend of Rs. 1.50 per equity share for the financial year ended on 31st March, 2022. The Dividend will be paid after approval of the same by shareholders in the Annual General meeting.

For and on behalf of Board of Directors  
for TITAN BIOTECH LIMITED

SURESH CHAND SINGLA  
Managing Director  
DIN-00027706



Place : Delhi


Dated :30.05.2022

**TITAN BIOTECH LIMITED**  
**Consolidated Balance Sheet as at 31st March, 2022**

(Rs. in Lakhs.)

Particulars	As at	
	31/03/2022 Audited	31/03/2021 Audited
<b>I ASSETS</b>		
<b>1. Non-Current Assets</b>		
a. Property, Plant and Equipment	2,695.68	2,620.90
b. Capital Work-in-Progress	796.63	27.05
c. Right of use Assets	1,509.60	730.59
d. Intangible assets	10.45	9.17
e. Other Non Current Assets	11.40	-
f. Financial Assets		
(i) Other Financial Assets	181.40	801.21
<b>Total Non-current assets</b>	<b>5,205.16</b>	<b>4,188.92</b>
<b>2. Current Assets</b>		
a. Inventories	4,229.46	3,253.77
b. Financial Assets		
(i) Trade receivables	2,167.08	1,810.39
(ii) Cash and cash equivalents	1,560.67	545.06
c. Current Tax Assets (Net)	-	-
d. Other Current Assets	1,177.51	273.42
<b>Total Current assets</b>	<b>9,134.72</b>	<b>5,882.64</b>
<b>TOTAL ASSETS</b>	<b>14,339.88</b>	<b>10,071.56</b>
<b>II. EQUITY AND LIABILITIES</b>		
<b>A Equity</b>		
a. Equity Share Capital	826.37	826.37
b. Other Equity	9,040.49	6,049.44
c. Non Controlling Interest	674.39	371.79
<b>TOTAL EQUITY</b>	<b>10,541.25</b>	<b>7,247.60</b>
<b>B Liabilities</b>		
<b>1. Non-Current Liabilities</b>		
a. Financial Liabilities		
(i) Borrowings	839.84	485.53
(ii) Lease liabilities	154.72	139.83
b. Deferred tax liabilities (Net)	130.73	138.92
c. Provisions	150.50	131.72
<b>Total Non-Current Liabilities</b>	<b>1,275.79</b>	<b>896.00</b>
<b>2. Current Liabilities</b>		
a. Financial Liabilities		
(i) Borrowings	747.00	828.53
(ii) Lease liabilities	33.37	25.02
(iii) Trade payables	754.79	371.35
(iv) Other Financial Liabilities	615.75	471.03
b. Other current liabilities	217.41	179.33
c. Provisions	28.87	17.00
d. Current Tax Liabilities (Net)	125.65	35.70
<b>Total Current Liabilities</b>	<b>2,522.84</b>	<b>1,927.96</b>
<b>TOTAL EQUITY AND LIABILITIES</b>	<b>14,339.88</b>	<b>10,071.56</b>

For and on behalf of Board of Directors  
for TITAN BIOTECH LIMITED

  
**SURESH CHAND SINGLA**  
Managing Director  
DIN-00027706



Place : Delhi  
Date : 30.05.2022

**TITAN BIOTECH LIMITED**  
**Consolidated Cash Flow Statement for the period ended 31st March, 2022**


(Rs. in Lakhs.)

Particulars	Year ended	Year ended
	31/03/2022	31/03/2021
	Audited	Audited
<b>A. CASH FLOW FROM OPERATING ACTIVITIES</b>		
Profit before Tax	3,819.83	4,270.56
Adjustment for :	-	-
Finance Costs	128.26	166.76
MAT Credit	-	-
Earlier year Taxes	(1.69)	(0.56)
Provision for employees Benefits	27.87	27.85
Depreciation and Amortization Expenses	253.84	221.73
Unamortized Expenses	-	0.30
Operating profit before working capital changes	4,228.11	4,686.64
Changes in working Capital:		
Inventories	(975.67)	(456.20)
Trade and other Receivables	(652.37)	(1,385.15)
Trade and other Payables	566.24	151.29
Cash generation from Operation	3,166.31	2,996.58
Payment of Direct Taxes	(880.39)	(1,088.37)
<b>Net Cash generated/ (used) - Operating Activities</b>	<b>2,285.92</b>	<b>1,908.21</b>
<b>B. CASH FLOW FROM INVESTMENT ACTIVITIES</b>		
Purchase of Fixed Assets (incl.Capital WIP and Right of use assets)	(1,099.49)	(301.08)
Right of use assets	(779.01)	(185.41)
<b>Net Cash Generated/ (Used) - Investing Activities</b>	<b>(1,878.50)</b>	<b>(486.49)</b>
<b>C. CASH FLOW FROM FINANCING ACTIVITIES</b>		
Repayment of Long-term Borrowings	272.79	(975.38)
Repayment of Lease Liabilities	23.25	164.85
Share application pending for allotment	564.37	-
Finance Cost paid	(128.26)	(166.76)
Dividend paid	(123.96)	(82.64)
<b>Net Cash Generated/ (Used) - Financing Activities</b>	<b>608.19</b>	<b>(1,059.93)</b>
<b>Net Increase/ (Decrease) in Cash and Cash Equivalents</b>	<b>1,015.61</b>	<b>361.79</b>
Add : Opening Cash and Cash Equivalents	545.06	183.27
<b>Closing Cash and Cash Equivalents</b>	<b>1,560.67</b>	<b>545.06</b>

**Notes:**

- The Cash Flow Statements have been prepared under the indirect method as set out in Accounting Standard (AS) on Statement of Cash Flow (Ind AS-7).
- Figures in bracket represent outflows.
- Previous year's figures have been regrouped wherever considered necessary to conform to this year's classification.

For and on behalf of Board of Directors  
for TITAN BIOTECH LIMITED

  
SURESH CHAND SINGLA  
Managing Director  
DIN-00027706



Place : Delhi  
Date : 30.05.2022



Office : 903-909, 9<sup>th</sup> Floor, Bigjos Tower, Netaji Subhash Place, Delhi-110034, India  
Tel. : 011-27355742, 71239900 (44 Lines) | Fax : +91-11-47619811 | CIN: L74999RJ1992PLC013387

**DISCLOSURE IN ACCORDANCE WITH REGULATION 52(4) OF SECURITIES AND EXCHANGE BOARD OF INDIA (LISTING OBLIGATIONS AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2015 FOR THE FINANCIAL YEAR ENDED 31<sup>st</sup> MARCH, 2022**

PARTICULARS		For the Financial Year ended	
		31.03.2022 (Audited)	31.03.2021 (Audited)
1	<b>Debt Equity Ratio</b> = Net Debt /Net Worth	0.1202	0.1747
2	<b>Debt Service Coverage Ratio</b>	14.61	9.41
3	<b>Interest Service Coverage Ratio</b>	40.98	33.30
4	<b>Net Worth</b> = (Equity Share Capital + Other Equity)	86,24,41,043.45	65,82,01,133.84
5	<b>Net profit after tax (Rs. In Lacs)</b>	2168.43	2877.27
6	<b>Basic Earnings per equity share</b> (In Rs.)	26.24	34.82
7	<b>Diluted Earnings per equity share</b> (In Rs.)	26.24	34.82
8	<b>Current Ratio</b>	3.85	3.40
9	<b>Long Term Debt to Working Capital</b>	0.08	0.13
10	<b>Bad Debts to Account Receivable Ratio</b>	N.A.	N.A.
11	<b>Current Liability Ratio</b>	0.82	0.76
12	<b>Total debt to total assets</b>	0.19	0.22
13	<b>Debtors Turnover Ratio</b>	7.61	9.19
14	<b>Inventory Turnover Ratio</b>	2.29	2.39
15	<b>Outstanding Redeemable Preference Shares</b> (Quantity and Value)	N.A.	N.A.
16	<b>Capital Redemption Reserve/Debenture Redemption</b>	N.A.	N.A.

R.O. & Works: Unit I: A-902 A, RIICO Industrial Area, Phase-III, Bhiwadi-301019, Rajasthan

Unit II: E-540, Industrial Area, Chopanki, Bhiwadi-301019, Rajasthan

E-mail: [marketing@titanbiotechltd.com](mailto:marketing@titanbiotechltd.com)

Website: [www.titanbiotechltd.com](http://www.titanbiotechltd.com) | [www.titanmedia.in](http://www.titanmedia.in)



# TITAN BIOTECH LTD.

AN ISO 9001:2015 CERTIFIED COMPANY



Office : 903-909, 9<sup>th</sup> Floor, Bigjos Tower, Netaji Subhash Place, Delhi-110034, India

Tel. : 011-27355742, 71239900 (44 Lines) | Fax : +91-11-47619811 | CIN: L74999RJ1992PLC013387

	<b>Reserve</b>		
17	<b>Operating Profit Margin (%)</b>	22.69%	31.45%
18	<b>Net Profit Margin (%)</b>	17.50%	23.88%
19	<b>Sector Specific Equivalent Ratios:</b> a. b. c.	N.A.	N.A.

Thanking you,  
Yours faithfully,  
For Titan Biotech Limited

  
**Charanjit Singh**  
Company Secretary  
Membership Number: A12726

  
**Prem Shankar Gupta**  
Chief Financial Officer



Date: 30/05/2022

R.O. & Works: Unit I: A-902 A, RIICO Industrial Area, Phase-III, Bhiwadi-301019, Rajasthan

Unit II: E-540, Industrial Area, Chopanki, Bhiwadi-301019, Rajasthan

E-mail: [marketing@titanbiotechltd.com](mailto:marketing@titanbiotechltd.com)

Website: [www.titanbiotechltd.com](http://www.titanbiotechltd.com) | [www.titanmedia.in](http://www.titanmedia.in)